Clinical trials
Trial starts, readouts, holds and designs.
Stories
-
Pharmazz, Inc. registers Phase 3 study of sovateltide for acute traumatic brain injury
The study, titled RESTORE-TBI, plans to enroll 214 participants and is scheduled to begin in December 2026. It is a prospective, multicenter, randomized, double-blind, placebo-controlled Phase III trial evaluating the efficacy and safety of sovateltide (IRL-1620) in patients with traumatic brain injury.
-
GlaxoSmithKline registers Phase 3 linerixibat safety eXtension study in Japan
The study plans to enroll 40 participants and start on October 9, 2026. It aims to assess the long-term safety of linerixibat in Japanese adults with cholestatic pruritus in primary biliary cholangitis (PBC) who previously participated in the linerixibat long-term safety and efficacy study, LLSAT (NCT04167358).
-
GlaxoSmithKline posts results of Phase 3 salbutamol safety study
Results for this study were first posted on ClinicalTrials.gov on October 6, 2026, for a Phase 3 trial that enrolled 471 participants. The study began May 31, 2024 and completed primary data collection on September 2, 2025.
-
Janssen posts results of Phase 3 aticaprant study in major depressive disorder
Results for the VENTURA-LT study of aticaprant (JNJ-67953964) were first posted on October 6, 2026. The open-label, long-term safety and efficacy study enrolled 871 participants, started on September 22, 2022, and completed primary data collection on April 25, 2025.
-
Vascular Therapies posts results of Phase 3 ACCESS 2 trial of Sirogen in ESRD patients
The ACCESS 2 trial, a Phase 3 study with 136 participants, evaluated the Sirolimus eluting Collagen implant (Sirogen) in patients undergoing arteriovenous fistula surgery. Results were first posted on ClinicalTrials.gov on October 6, 2026, after the study's primary completion on March 18, 2025.
-
GL Pharm Tech Corporation registers Phase 3 trial of W2505 for erectile dysfunction
The study, first posted on ClinicalTrials.gov on October 5, 2026, plans to enroll 228 participants and begin in September 2026. It is a prospective, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of W2505.
-
Chiesi registers Phase 3 trial of CHF5993 vs Seretide in adolescent asthma
The study, first posted on ClinicalTrials.gov on October 5, 2026, plans to enroll 700 participants and start on November 16, 2026. It compares CHF5993 100/6/12.5 μg pMDI to Seretide Evohaler 125/25 μg pMDI over 52 weeks in adolescents with uncontrolled asthma.
-
Genmab registers Phase 3 trial of Rina-S in ovarian cancer
The study plans to enroll 602 participants and is expected to start in November 2026. It compares Rina-S alone or in combination with an approved standard of care treatment against the same available standard of care therapy by itself, or no treatment.
-
Incyte posts results of Phase 3 axatilimab trial in chronic graft-versus-host disease
Results for the Phase 3, open-label study of axatilimab in Japanese participants with recurrent or refractory active chronic graft-versus-host disease were first posted on ClinicalTrials.gov on October 5, 2026. The study enrolled 21 participants and completed primary data collection on August 6, 2025.
-
Intra-Cellular Therapies, Inc. posts results of Lumateperone schizophrenia relapse study
The Phase 3 study enrolled 592 participants and was completed with primary completion on July 25, 2024. Results were first posted on ClinicalTrials.gov on October 5, 2026.
-
Boehringer Ingelheim registers Phase 3b trial of Survodutide in MASLD
This study was first posted on ClinicalTrials.gov on September 30, 2026. The trial plans to enroll 600 participants and planned start date is October 23, 2026.
-
Intra-Cellular Therapies registers JNJ-99245354 (ITI-1284) in generalized anxiety disorder
This study was first posted on ClinicalTrials.gov on October 2, 2026. The trial plans to enroll 705 participants and has a planned start date of September 30, 2026, with a primary completion date of September 20, 2030.